JP2004506009A - インスリン抵抗性症候群の治療 - Google Patents
インスリン抵抗性症候群の治療 Download PDFInfo
- Publication number
- JP2004506009A JP2004506009A JP2002518944A JP2002518944A JP2004506009A JP 2004506009 A JP2004506009 A JP 2004506009A JP 2002518944 A JP2002518944 A JP 2002518944A JP 2002518944 A JP2002518944 A JP 2002518944A JP 2004506009 A JP2004506009 A JP 2004506009A
- Authority
- JP
- Japan
- Prior art keywords
- ethyl
- dihydro
- pyrazolo
- pyrimidin
- sildenafil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- GXESHMAMLJKROZ-IAPPQJPRSA-N Oc1ccc([C@H]([C@H](CC2)c3ccccc3)c(cc3)ccc3OCCN3CCCC3)c2c1 Chemical compound Oc1ccc([C@H]([C@H](CC2)c3ccccc3)c(cc3)ccc3OCCN3CCCC3)c2c1 GXESHMAMLJKROZ-IAPPQJPRSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22492800P | 2000-08-11 | 2000-08-11 | |
GB0030649A GB0030649D0 (en) | 2000-12-15 | 2000-12-15 | Treatment of the insulin resistance syndrome |
US26608301P | 2001-02-02 | 2001-02-02 | |
GB0106468A GB0106468D0 (en) | 2001-03-15 | 2001-03-15 | Treatment of diabetes mellitus |
GB0106465A GB0106465D0 (en) | 2001-03-15 | 2001-03-15 | Treatment of the insulin resistance syndrome |
GB0117134A GB0117134D0 (en) | 2001-07-13 | 2001-07-13 | Treatment of the insulin resistance syndrome |
PCT/IB2001/001428 WO2002013798A2 (en) | 2000-08-11 | 2001-08-06 | Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2004506009A true JP2004506009A (ja) | 2004-02-26 |
JP2004506009A5 JP2004506009A5 (ko) | 2005-02-24 |
Family
ID=27546614
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002518944A Withdrawn JP2004506009A (ja) | 2000-08-11 | 2001-08-06 | インスリン抵抗性症候群の治療 |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1307183A2 (ko) |
JP (1) | JP2004506009A (ko) |
KR (1) | KR20030023747A (ko) |
CN (1) | CN1446084A (ko) |
AU (1) | AU2001276607A1 (ko) |
CA (1) | CA2419033A1 (ko) |
HU (1) | HUP0300725A3 (ko) |
IL (1) | IL154158A0 (ko) |
WO (1) | WO2002013798A2 (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021506983A (ja) * | 2017-12-19 | 2021-02-22 | マレシル リサーチ アンド テクノロジー エルエルシー | 糖尿病性足潰瘍の治療方法 |
JP7483716B2 (ja) | 2018-12-21 | 2024-05-15 | コリア ベーシック サイエンス インスティテュート | Cyp4a阻害化合物を有効成分として含む代謝疾患の予防または治療用組成物 |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2436576A1 (en) * | 2001-02-02 | 2002-08-08 | Pfizer Inc. | Treatment of diabetes mellitus using vardenafil |
US6933127B2 (en) | 2001-07-05 | 2005-08-23 | Eucro European Contract Research Gmbh & Co. Kg | Substrate for PP2C |
DE10135815A1 (de) * | 2001-07-23 | 2003-02-06 | Bayer Ag | Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen |
US7019010B2 (en) | 2001-09-27 | 2006-03-28 | Novertis Ag | Combinations |
US20030114469A1 (en) * | 2001-09-27 | 2003-06-19 | Cohen David Saul | Combinations |
IL161155A0 (en) * | 2001-11-02 | 2004-08-31 | Pfizer Prod Inc | Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors |
US20030181461A1 (en) * | 2002-01-25 | 2003-09-25 | Lautt Wilfred Wayne | Use of phosphodiesterase antagonists to treat insulin resistance |
AU2003205926A1 (en) * | 2002-02-07 | 2003-09-02 | Pfizer Limited | Use of pde5 inhibitors such as sildenafil in the treatment of polycystic ovary syndrome |
JP2004018524A (ja) * | 2002-06-13 | 2004-01-22 | Eucro European Contract Research Gmbh & Co Kg | 動脈硬化症を処置するための方法 |
GB0214784D0 (en) * | 2002-06-26 | 2002-08-07 | Pfizer Ltd | Novel combination |
WO2004082667A1 (en) * | 2003-03-17 | 2004-09-30 | Pfizer Products Inc. | Treatment of type 1 diabetes with pde5 inhibitors |
OA13050A (en) | 2003-04-29 | 2006-11-10 | Pfizer Ltd | 5,7-diaminopyrazolo [4,3-D] pyrimidines useful in the treatment of hypertension. |
CN100439371C (zh) * | 2003-04-29 | 2008-12-03 | 辉瑞大药厂 | 可用于治疗高血压的5,7-二氨基吡唑并[4,3-d]嘧啶 |
JP2007504201A (ja) | 2003-09-05 | 2007-03-01 | アルタナ ファルマ アクチエンゲゼルシャフト | 真性糖尿病の治療のためのpde4阻害剤の使用 |
US7572799B2 (en) | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
US7569572B2 (en) | 2004-04-07 | 2009-08-04 | Pfizer Inc | Pyrazolo[4,3-D]pyrimidines |
WO2006094933A1 (en) | 2005-03-08 | 2006-09-14 | Nycomed Gmbh | Roflumilast for the treatment of diabetes mellitus |
EP1909793A2 (de) * | 2005-07-15 | 2008-04-16 | Proxomed Medizintechnik GmbH | Verwendung von phosphodiesterase typ 5-hemmern für die prävention und behandlung von erkrankungen oder gesundheitsstörungen, sowie abgabesysteme für dieselben |
MEP8509A (en) | 2006-09-07 | 2011-12-20 | Combination treatment for diabetes mellitus | |
MX2009013354A (es) | 2007-06-04 | 2010-07-06 | Univ Ben Gurion | Compuestos de triarilo y composiciones que los contienen. |
AT512084A1 (de) | 2011-10-20 | 2013-05-15 | Univ Wien Tech | Diazabicyclo- und diazaspiro-alkanderivate als phosphodiesterase-5 inhibitoren |
WO2013173923A1 (en) | 2012-05-25 | 2013-11-28 | Diamedica, Inc. | Formulations of human tissue kallikrein-1 for parenteral delivery and related methods |
CA2880085C (en) | 2012-06-04 | 2021-09-07 | Diamedica Inc. | Human tissue kallikrein 1 glycosylation isoforms |
CN108452311A (zh) * | 2012-11-13 | 2018-08-28 | 纽斯尔特科学公司 | 用于增强能量代谢的组合物和方法 |
US9840547B2 (en) | 2013-05-14 | 2017-12-12 | Scimar Ltd. | Hepatic insulin sensitizing substance and test meal for insulin sensitization |
WO2015068156A1 (en) | 2013-11-05 | 2015-05-14 | Ben-Gurion University Of The Negev Research And Development Authority | Compounds for the treatment of diabetes and disease complications arising from same |
CN110446501A (zh) | 2017-03-09 | 2019-11-12 | 代阿麦迪卡股份有限公司 | 组织激肽释放酶1的剂型 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9013750D0 (en) * | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
GB9511220D0 (en) * | 1995-06-02 | 1995-07-26 | Glaxo Group Ltd | Solid dispersions |
US6166219A (en) * | 1995-12-28 | 2000-12-26 | Fujisawa Pharmaceutical Co., Ltd. | Benzimidazole derivatives |
WO1998049166A1 (en) * | 1997-04-25 | 1998-11-05 | Pfizer Limited | PYRAZOLOPYRIMIDINONES WHICH INHIBIT TYPE 5 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (cGMP PDE5) FOR THE TREATMENT OF SEXUAL DYSFUNCTION |
RU2199532C2 (ru) * | 1997-06-27 | 2003-02-27 | Фудзисава Фармасьютикал Ко., Лтд. | Сульфонамидное соединение |
WO1999051574A1 (fr) * | 1998-04-06 | 1999-10-14 | Fujisawa Pharmaceutical Co., Ltd. | Derives d'indole |
KR20010086593A (ko) * | 1998-12-04 | 2001-09-13 | 후지야마 아키라 | 술폰아미드 화합물 및 그의 의약 용도 |
ID30182A (id) * | 1999-03-22 | 2001-11-08 | Bristol Myers Squibb Co | PENGHAMBAT-PENGHAMBAT PIRIDOPIRIDAZINA LEBURAN DARI cGMP FOSFODIESTERASE |
DE19944161A1 (de) * | 1999-09-15 | 2001-03-22 | Bayer Ag | Neue Kombination zur Behandlung von sexueller Dysfunktion |
EP1088824B1 (en) * | 1999-09-30 | 2004-01-07 | Pfizer Products Inc. | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors |
CA2323008C (en) * | 1999-10-11 | 2005-07-12 | Pfizer Inc. | Pharmaceutically active compounds |
CA2406947A1 (en) * | 2000-04-19 | 2001-10-25 | Johns Hopkins University | Methods for prevention and treatment of gastrointestinal disorders |
-
2001
- 2001-08-06 JP JP2002518944A patent/JP2004506009A/ja not_active Withdrawn
- 2001-08-06 KR KR10-2003-7001961A patent/KR20030023747A/ko not_active Application Discontinuation
- 2001-08-06 WO PCT/IB2001/001428 patent/WO2002013798A2/en not_active Application Discontinuation
- 2001-08-06 AU AU2001276607A patent/AU2001276607A1/en not_active Abandoned
- 2001-08-06 HU HU0300725A patent/HUP0300725A3/hu unknown
- 2001-08-06 EP EP01954266A patent/EP1307183A2/en not_active Withdrawn
- 2001-08-06 CN CN01814039A patent/CN1446084A/zh active Pending
- 2001-08-06 IL IL15415801A patent/IL154158A0/xx unknown
- 2001-08-06 CA CA002419033A patent/CA2419033A1/en not_active Abandoned
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021506983A (ja) * | 2017-12-19 | 2021-02-22 | マレシル リサーチ アンド テクノロジー エルエルシー | 糖尿病性足潰瘍の治療方法 |
JP7483716B2 (ja) | 2018-12-21 | 2024-05-15 | コリア ベーシック サイエンス インスティテュート | Cyp4a阻害化合物を有効成分として含む代謝疾患の予防または治療用組成物 |
Also Published As
Publication number | Publication date |
---|---|
HUP0300725A2 (hu) | 2003-11-28 |
HUP0300725A3 (en) | 2005-11-28 |
WO2002013798A2 (en) | 2002-02-21 |
KR20030023747A (ko) | 2003-03-19 |
EP1307183A2 (en) | 2003-05-07 |
AU2001276607A1 (en) | 2002-02-25 |
CA2419033A1 (en) | 2002-02-21 |
IL154158A0 (en) | 2003-07-31 |
WO2002013798A3 (en) | 2003-01-23 |
CN1446084A (zh) | 2003-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20030166662A1 (en) | Treatment of the insulin resistance syndrome | |
JP2004506009A (ja) | インスリン抵抗性症候群の治療 | |
US6683080B2 (en) | Treatment of diabetes mellitus | |
JP2004527476A5 (ko) | ||
ZA200402173B (en) | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors. | |
US20080153841A1 (en) | Treatment of premature ejaculation | |
US20040186046A1 (en) | Treatment of type 1 diabetes with PDE5 inhibitors | |
US20040029891A1 (en) | Use of PDE5 inhibitors in the treatment of polycystic ovary syndrome | |
CA2474852A1 (en) | Use of pde5 inhibitors in the treatment of scarring and fibrosis | |
KR20050004195A (ko) | 신규 조합 제제 | |
JP2006520777A (ja) | Pde5阻害剤を用いる1型糖尿病の治療 | |
EP1524996A2 (en) | Combination of pde5 inhibitors with angiotensin ii receptor antagonists | |
US20040132731A1 (en) | Novel combination | |
KR100595807B1 (ko) | 조루 치료법 | |
AU2002215149A1 (en) | Treatment of premature ejaculation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20060511 |